LPCN Latest Press Releases

-- January 20, 2026 --

Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) PRNewswire 8:00 AM

-- January 19, 2026 --

2026 Asset Growth: Why Federal Compliance Is the New Metric Globe Newswire 12:20 PM

-- January 12, 2026 --

Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) PRNewswire 8:00 AM

-- December 16, 2025 --

Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone PRNewswire 8:00 AM

-- November 18, 2025 --

Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) PRNewswire 8:00 AM

-- November 6, 2025 --

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025 PRNewswire 8:00 AM

-- November 4, 2025 --

Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek PRNewswire 8:01 AM

-- September 30, 2025 --

Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD) PRNewswire 8:02 AM

-- September 5, 2025 --

Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference PRNewswire 4:30 PM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software